Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
about
Targeted drugs in small-cell lung cancerClinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancerTargeting angiogenesis in small cell lung cancerAngiogenesis inhibitors for the treatment of small cell lung cancer (SCLC): A meta-analysis of 7 randomized controlled trials.Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).Small cell lung cancer: therapies and targetsEffect of cediranib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in a mouse model of choroidal neovascularization.Development of second-generation VEGFR tyrosine kinase inhibitors: current status.Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysisABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Small cell lung cancer: will recent progress lead to improved outcomes?Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.Anti-VEGF therapies in the clinicTargeted therapies in small cell lung cancerEfficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II studySmall Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.The development of targeted therapy in small cell lung cancer.Advances in antiangiogenic treatment of small-cell lung cancer.Research progress in the treatment of small cell lung cancer.Cancer stem cells: the development of new cancer therapeutics.Novel strategies for the treatment of small-cell lung carcinoma.Cediranib: a VEGF receptor tyrosine kinase inhibitor.Advances in pharmacotherapy of small cell lung cancer.An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.Progress and challenges in the treatment of small cell lung cancer.Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.Second-line treatments of small-cell lung cancers.A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
P2860
Q26767017-9A82A460-E8B4-4CE5-8782-3B93E49261ECQ27024235-0B8EDF4A-0ECB-40F3-9CA4-984DB4A35CBEQ28068385-B46CD19A-48FC-47ED-9357-F2D1F464BC34Q30235046-BFD7B216-5ED0-436E-A98C-882F618759D6Q33420821-D651DAEB-FE52-493A-9D84-CD93CF1A353FQ34250859-10515638-135E-443F-804D-5BB48B244AD8Q34272439-9AA0B72C-6B01-4777-B6A4-213241B46C8DQ34616440-A16FF0EF-E90D-495F-835A-CDB7E8E24DB6Q35118673-124AB86B-6928-4689-AC8B-4E254CBC9A6EQ35171274-26AFDE9A-6EE6-4CD2-9B7F-22F10BCEA79BQ35836257-79123467-E720-4215-B0F8-E659F4E5FBFBQ35913169-DBEF0A16-824A-459B-A644-D8926085C118Q36330281-5B23E8CF-A54C-43D1-9102-34B418097D18Q36475811-8959D12C-9F5A-4B2E-AD6B-8C560CAF27BDQ36720049-15470996-FD3B-4E40-8B2B-DB79AC578747Q36811784-BA6CB7DD-3C94-4202-8D99-36A74CC432C7Q36864032-BD24B1C9-A563-4244-BE96-35E081F4F78AQ37127932-A80C6167-429D-46B9-A2ED-CFCCA0AD9445Q37588040-F04F6D47-9275-45B9-9D9E-B477B28D4DD6Q37604301-8E1A4C37-1F46-4E05-BC30-007F5B0F4AE5Q37861207-DC07A5BF-71DD-4CA3-9D39-F96740110D87Q37892341-E8EDC867-64BB-4467-A3B1-A8EEE883488DQ38029363-DDA94F84-4FEF-496D-995B-A7F8D32068BFQ38254295-AF6B842A-C618-4C83-A6BC-23D0C69E9243Q38525073-6FE90241-471C-4E5C-965A-7FD2A1EA3C9EQ39272825-233FBA4A-85DA-4D87-A9BF-9772FB390C8AQ45304925-E801848B-C74A-4149-B119-E1E1433E6C3EQ47789861-46527E73-179D-4046-AFE5-A2DFF90CAD34Q48374393-3207CB57-97F7-448F-B655-F5FD0FC5565AQ51658011-996DAA1F-53A0-46D7-B624-D75F7ACA3936Q53740020-D00E4229-0563-44D0-85DC-01A96A6EFD50
P2860
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase II study of Cediranib (A ...... ional Cancer Institute #7097).
@ast
Phase II study of Cediranib (A ...... ional Cancer Institute #7097).
@en
Phase II study of Cediranib (A ...... ional Cancer Institute #7097).
@nl
type
label
Phase II study of Cediranib (A ...... ional Cancer Institute #7097).
@ast
Phase II study of Cediranib (A ...... ional Cancer Institute #7097).
@en
Phase II study of Cediranib (A ...... ional Cancer Institute #7097).
@nl
prefLabel
Phase II study of Cediranib (A ...... ional Cancer Institute #7097).
@ast
Phase II study of Cediranib (A ...... ional Cancer Institute #7097).
@en
Phase II study of Cediranib (A ...... ional Cancer Institute #7097).
@nl
P2093
P2860
P50
P1476
Phase II study of Cediranib (A ...... ional Cancer Institute #7097).
@en
P2093
Chandra P Belani
Marianna Koczywas
Philip C Mack
Ramaswamy Govindan
S Percy Ivy
Suresh S Ramalingam
P2860
P304
P356
10.1097/JTO.0B013E3181E2FCB0
P577
2010-08-01T00:00:00Z